Tanya Simuni, MDS 2020 – Update on Clinical Trials in Parkinson’s Disease
We were fortunate to have the opportunity to speak with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) following her session entitled: Update on Recent Clinical Trials – Parkinson’s Disease.
Questions
1. Could you give us a brief overview of the role of α-synuclein in the pathogenesis of Parkinson’s disease (PD) and its potential as a therapeutic target? (0:06)
2. What are the advantages and limitations of α-synuclein immunotherapies? (1:03)
3. Could you give us an overview of the rationale for targeting glucagon-like peptide (GLP-1) agonists and progress to date? (2:33)
4. What other therapeutic targets are in advanced clinical development? (4:13)
5. What are the challenges of identifying genetic PD and how are these challenges being met? (4:59)
Disclosures: Prof. Simuni reports receiving grants from NINDS, MJFF and Parkinson’s Foundation; support from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Abbvie, IMPAX, Prevail; and other from Acadia, Abbvie, Accorda , Adamas, Allergan, Amneal, Aptinyx, Denali, General Electric (GE), Kyowa, Neuroderm, Neurocrine, Sanofi, Sinopia, Sunovion, Roche, Takeda, Voyager and US World Meds.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.
